Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 3 Clinical Trial of ALLO-ASC-DFU-301

NCT04590703 is registered in ClinicalTrials.gov with Anterogen Co., Ltd. as lead sponsor.

NCT NCT04590703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04590703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 3 Clinical Trial of ALLO-ASC-DFU-301
Lead sponsor
Anterogen Co., Ltd.
Phase
Observational
Overall status
Completed
Start date
June 24, 2020
Completion date
June 2, 2023
Enrollment
73 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic foot ulcer